\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\AtBeginDocument{\let\citet\cite\let\citep\cite}
\usepackage[numbers,sort&compress,numbers,sort&compress]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{https://ijrps.com}{\color{blue}\underline{\smash{https://ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Feature enabled:
%citation-style: unsrt
%citation-type: numbered
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[flushleft]{threeparttablex}

\usepackage{float}

\begin{document}


\def\RunningAuthor{P. Bharathi et al.}
\firstPage{88}
\articleType{Original Article}
\receivedDate{10 Dec 2022}
\acceptedDate{14 Jan 2023}
\revisedDate{12 Jan 2023}
\journalVolume{2023, 14}
\journalIssue{1}
\journalDoi{ijrps.v14i2.4283}
\copyrightYear{2023}
\issuelogo{2a083ea5-3f5f-4c89-b3ee-a9be358d63fa-unew-logo}
\issuelogoex{png}
\def\authorCount{5}
\def\affCount{3}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{\textbf{Formulation and evaluation of Risperidone orally disintegrating tablets}}
\author{P.~Bharathi\textsuperscript{*}\textsuperscript{1}\textsuperscript{\href{https://orcid.org/0009-0009-5435-1600}{\XeTeXLinkBox{\includegraphics[height=7pt]{orcid-logo-pharmascope.pdf}}}},  
            S.~Jayaprakash\textsuperscript{1}\textsuperscript{\href{https://orcid.org/0000-0001-6543-0990}{\XeTeXLinkBox{\includegraphics[height=7pt]{orcid-logo-pharmascope.pdf}}}},  
            A.~Abirami\textsuperscript{1},  
            S.~Samera\textsuperscript{2}, 
            R.~Venkatesh~Babu\textsuperscript{3}\textsuperscript{\href{https://orcid.org/0009-0007-1067-3558}{\XeTeXLinkBox{\includegraphics[height=7pt]{orcid-logo-pharmascope.pdf}}}}~\\[5pt]{\textsuperscript{1}Department of Pharmaceutics, K.M.College of Pharmacy, Madurai, Tamilnadu, India}~\\{\textsuperscript{2}Department of Pharmacy Practice, K.M.College of Pharmacy, Madurai}~\\{\textsuperscript{3}Research and Development, Pharmafabrikon, Madurai, Tamilnadu, India}}

\begin{abstract}
Most people have difficulty swallowing, particularly the geriatric or pediatric population. Tablets have many advantages such as cost-effectiveness, compactness, least variability of contents of all oral dosage forms. Oral Disintegrating Tablets (ODT) are dissolving tablets that are solid oral dosage forms that break down into a swallowable form without additional water. There are many properties such as it should break down without additional water, easily transportable. Chemicals such as Mannitol, Sorbitol, Propyl paraben, Methyl paraben, Crospovidone, etc. are used for manufacturing ODTs. The formulation steps for the tablet are sieving, dry mixing, lubrication, and compression. ODTs are evaluated for friability, thickness, hardness and weight variation. Formulation-I contained 2mg Risperidone,121.60mg Mannitol anhydrous, 11.20mg sodium starch glycollate, 0.80mg methylparaben, 0.20mg propylparaben, 1.40mg Aspartame, 0.7mg Sunset yellow, 1.40mg Strawberry flavour, and 0.70mg Magnesium stearate. Each formulation from F-II to F-VII were made by changing the composition compared to F-I. Using a pH 1.2 buffer, Risperidone calibration curves were analyzed using HPLC. There were straight-line relationships for Risperidone standard solution in Media at a concentration of 0-10 \ensuremath{\mu }g/ml. Physico-chemical parameters such as Loose Bulk Density (LBD), Angle of Repose, Tapped Bulk Density (TBD), Drug content (\%) and Compressibility index (\%) were analyzed for FI- F-VII. The cumulative percentage drug release of F-I is 96.50, F-II is 99.65, F-III is 99.82, F-IV is 98.56, F-V is 98.25, F-VI is 99.73 and F-VII is 99.82. F-I - F-VII formulations were compared to marketed sample (ZISPER MD 2mg). Stability Data of Risperidone F-VII Orally disintegrating Tablets at two different temperatures were carried out.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Risperidone,\newline Formulation,\newline Evaluation,\newline Tablets
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ P.~Bharathi~\\ Phone:\ 9597227780~\\  Email:\ bharathibh741@gmail.com
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{https://ijrps.com}{https://ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Dysphagia or difficulty swallowing affects about one third of the population. Patients with difficulty swallowing are most likely to be geriatric or pediatric. Schizophrenic patients can also have difficulty swallowing because of hand tremors, dysphasia, fear of choking, and underdeveloped nervous and muscular systems\unskip~\cite{1927116:28000239}.

\textbf{Pediatric Dosage Forms }

Pharmacists are constantly adapting to maximize patient compliance, which is the most important factor in pediatric drug administration. In accordance with WHO guidelines, an ideal drug delivery system for children must be easy to administer, palatable, able to be titrated and administered based on weight, as well as contain safe, well-established and stable excipients\unskip~\cite{1927116:28000243}.

\textbf{Liquid Dosage Forms}

As a result of the variable dosing and palatable nature of liquid oral dosage forms, they were considered the best way to administer medications to children\unskip~\cite{1927116:28000236}.

\textbf{Solid Dosage Forms }

There is a considerable difference between administering drugs as pure chemical substances and administering them as prepared preparations. 

\textbf{Advantages of tablets}

Tablets can provide the following primary benefits

The unit dosage form is the least variable oral dosage form in terms of dosage precision and content variability.

Among all oral dosage forms, this has the lowest cost.

Their lightness and compactness make them the most desirable\unskip~\cite{1927116:28000242}.

\textbf{Disadvantages}

Tablets still have some disadvantages despite all their advantages. In addition to their advantages, tablets also have some disadvantages:

Drugs that are amorphous or flocculent and low-density resist compressed into dense compacts.

In the case of poorly wetting, slow dissolving, intermediate or large dosages, or high absorption in the gastrointestinal tract, formulation and manufacture of tablets that are adequate in bioavailability may be difficult or impossible.

\textbf{Orally Disintegrating Tablets\ensuremath{^{}}}

Children who swallow tablets can suffer from aspiration risks and swallowing difficulties, which can cause complications with traditional tablets. Pediatric patients are typically less at risk of aspirating with oral disintegrating tablets (ODTs). Oral disintegrating tablets are solid oral dosage forms that disintegrate without additional water in the oral cavity into a form that can be swallowed. Due to their non-water or chewing requirements, ODTs are beneficial. There are many advantages to these drugs, including superior taste, increased bioavailability, improved efficacy, improved stability, variable dosing, and lowered costs. Furthermore, more than half of patients prefer ODTs to tablets or other forms of dosage.

\textbf{Ideal properties of orally disintegrating tablets}

\ensuremath{^{}}Tablets that disintegrate orally should follow,



\begin{itemize}
  \item \relax Swallow without the need for water or other liquids.
  \item \relax Within a few seconds, it dissolves or disintegrates in saliva.
  \item \relax Taste good.
  \item \relax If administered, Mouth residue will be minimal.
  \item \relax Transport and portability are important\unskip~\cite{1927116:28000245}.
\end{itemize}
  \textbf{Techniques for preparing orally disintegrating tablets}

In order to formulate oral disintegrating tablets, several techniques have been reported \unskip~\cite{1927116:28411167}.

\begin{itemize}
  \item \relax Tablet Moulding
  \item \relax Freeze drying / lyophilization
  \item \relax Sublimation
  \item \relax Spray drying
  \item \relax Mass extrusion
  \item \relax Direct compression
\end{itemize}
  
    
\section{Materials and Methods}
Risperidone was procured from JPN Pharma Private Limited, Cellulose, Microcrystalline from Ankit pulps and boards Private Limited, Mannitol from Quingdao bright moon sea wood, Sorbitol-Roquette, Propyl paraben and Methyl paraben purchased from Rasula pharmaceuticals and fine chemicals, Starch, pre-gelatinized was from Universal starch chem allied ltd., Croscarmellose sodium from Prachin chemicals, Crospovidone-International fine chemicals, Sodium starch glycolate-Vasa pharma chem pvt ltd., Magnesium stearate - Accent microcell pvt ltd., Sunset yellow-Roha dye chem. Pvt ltd

Equipment used in each company were Blister Packing Machine - Elmach packages pvt ltd, Mumbai, India, Single pan electronic balance; Dissolution Test Apparatus - Electro Lab, Mumbai, India; 12 Station D/B Tooling compression Machine Blister Packing Machine - Fluid pack, Ahmedabad

\textbf{Formulation steps for tablets (Direct compression) }

Table~\ref{tw-e2ba6a9e0cc6} shows how oral disintegrating tablets of Risperidone (2 mg) were prepared using direct compression (without granulating step). Formulation codes FI-FVII were prepared using direct compression. Sieving, dry mixing, lubrication, and compression are the steps involved in Direct Compression Method tablet production\unskip~\cite{1927116:28000249}.

\textbf{Sieving}

In Table 4, the active ingredient and the other ingredients (described in formulation codes F-I to F-VII) were passed through sieve number 40.

\textbf{Dry mixing }

To ensure uniform mixing of the active ingredient and all the ingredients, all the ingredients were placed in poly bags and mixed for 10 mins.

\textbf{Lubrication }

It was mixed with the powder mixture, magnesium stearate, talc and sieve \# 60 for 5 minutes in a polybag to achieve a uniform blend.\textit{\space }

\textbf{Compression }

A tablet shape of 7.14 mm was then used to compress the powder mixture into tablets. One machine compresses tablets using rotary punches.

\textbf{Packing Details}

Packing specifications for the prepared tablets were as follows: 10 tablets were packaged in PVC-Aluminum blister packets.

\textbf{Evaluation of orally dispersible tablets }

\textbf{Thickness }

Tablet thickness is the only overall dimensional variable once tablet size and shape are determined. An established thickness standard should not be exceeded by more than 5\%. Packaging and consumer acceptance can be affected by excessive variation in tablet thickness. It is also possible to determine force from variations in tablet thickness. Table 6 reports the average tablet thickness using vernier callipers used for measuring wet granulation and direct compression tablets we prepared\unskip~\cite{1927116:28000247}.

\textbf{Hardness}

During manufacturing, packing, shipping, and dispensing, tablets must be mechanically strong enough to withstand shock. Drugs with sustained release profiles or those that can be sensitive to changes in release profiles may require monitoring tablet hardness more often. A hardness tester is used by Monsanto to measure a tablet's crushing strength. Plungers 1 and 2 hold the tablet vertically. When the tablet was placed on the plunger, the first reading was taken. Tablet fractured when a bolt was turned against a spring. The gauge on the barrel indicates the pressure when the spring is compressed. Comparing the initial and final readings, along with noting the position of the pointer at fracture is done.

\textbf{Weight Variation}

Following Indian Pharmacopoeia guidelines, weight variation tests of the tablets were performed. The average weight was determined from the weights of twenty tablets selected at random. Based on Table~\ref{tw-1d44d638069e} , deviations from the mean were calculated for each tablet. Two individual weights are more than 5\% off from the average weight, and none are more than double off.

\textbf{Friability}

In manufacturing, packaging, shipping, and consumer use, a tablet's friability is its ability to resist shock and abrasion without crumbling. Consumers do not accept tablet technology that powders, chips, and fragments when handled because of its lack of elegance. A friability of the Roche type was used to measure the weight of 10 tablets. During each revolution, a plastic chamber rotates at 25 revs, rolling the tablets six inches at a time, causing shock and abrasion. It is then removed, dusted, and reweighed after 100 revolutions. In general, tablets are considered acceptable if they lose less than 0.5 to 1 percent of their weight [9]. According to Table~\ref{tw-1d44d638069e} , the Risperidone-loaded tablets had a high degree of friability.

\textbf{Rapidly Disintegrating Property \ensuremath{^{}}}

Following are the tests carried out to determine whether the tablets disintegrate quickly.\ensuremath{^{}}

\textbf{Wetting time}

Petri dishes with 10cm diameters are filled with five circular tissue papers of 10cm diameter. To the Petri dish is added millilitres of water-soluble dye Eosin, a water-soluble dye. On the tissue paper, a tablet is carefully placed. During wetting time, water reaches the upper surface of the tablet.

\textbf{Modified disintegration test}

These dosage forms cannot be tested according to the standard disintegration test procedure since their disintegration times are very short. To minimize disintegration in the delivery contents, the disintegration time for ODT must be modified since the test requires disintegration without water. The water was poured into a Petri dish (10 cm in diameter). After the tablet was placed in the Petri dish, it took a long time for it to decompose completely.

\textbf{Water absorption ratio}

We put 6ml of water in a Petri dish with a folded piece of tissue paper. The paper was wetted completely by placing a tablet on it and measuring the time it took. We then weighed the wet tablet. Based on the equation below, we were able to calculate the water absorption ratio, R.

R=100 (Wa-Wb/Wb)

Wa is After absorption, tablet weight

Wb is Before absorption, tablet weight 

\textbf{Disintegration test}

The apparatus should be operated at 24\ensuremath{^\circ}C to 26\ensuremath{^\circ}C for three minutes at that temperature Figure~\ref{f-d3814e3aed47}\unskip~\cite{1927116:28000234}.

\textbf{Uniformity of Dispersion}

Stir gently until completely dispersed after placing two tablets in 100ml of water. Smooth dispersion results from passing through a sieve screen with a nominal aperture of 710 \ensuremath{\mu} (Sieve number 22) \unskip~\cite{1927116:28000250}Tables~\ref{tw-1d44d638069e} and~\ref{tw-ee40ece25195}

\textbf{Drug content} estimation of the weight of each tablet was known before each batch of tablets was triturated to form a fine powder. Twenty ml of methanol was used to extract the powder equivalent to 2 mg of Risperidone. An ultrasonicator was used to keep the resulting solution for 15 minutes. With the addition of the mobile phase, the volume of the solution reached 50 ml after 15 minutes. Next, a 0.45 mm membrane was used to filter the solution. HPLC systems with the following chromatographic conditions were used to inject the solution;



\begin{itemize}
  \item \relax HPLC method for Risperidone estimation in tablet formulations
  \item \relax Liquid Chromatographic Conditions:
  \item \relax Mobile phase : 30 Volume Acetonitrile, 20 Volume Methanol,50Volume Buffer
  \item \relax Column : OYSTER C18, 250 \ensuremath{\times} 4.6mm, 5 \ensuremath{\mu } 
  \item \relax Buffer : 0.20ml triethylamine in 500ml Water adjust pH 4.0 with orthophosphoric acid
  \item \relax Temperature : ambient
  \item \relax Injection volume : 20 \ensuremath{\mu}l
  \item \relax Detection: Risperidone-220 nm
  \item \relax Flow rate: 1.0 ml/minute
\end{itemize}
  \textbf{Preparation of mobile phase}

A mixture of 40 ml of Acetonitrile and 60 ml of demineralised water was filtered using a 0.45 \ensuremath{\mu}m -sized membrane. A 0.22 \ensuremath{\mu}m -sized membrane was then used to filter the mobile phase, followed by ultrasonic degassing. A temperature of 20\ensuremath{^\circ}C was used for the experiments.

As can be seen in Table 6, each tablet formulation contains different amounts of drug.

\textit{\textbf{In vitro}} \textbf{ Dissolution Studies}

USP apparatus type II at 50 rpm was used for the in vitro dissolution studies. We used 0.1N hydrochloric acid for the dissolution medium (500 ml), which was maintained at 37\ensuremath{^\circ}C \ensuremath{\pm} 0.5\ensuremath{^\circ}C. At 220 nm (Waters Technologies), HPLC was used to measure the drug release over time. There was no interference with the assay due to any of the ingredients in the formulations. As shown in the release studies, when performed in triplicate, the results were reproducible with SDs of less than 3. (6 tablets in each set). There are cumulative percent releases of Risperidone from the developed tablet formulations (F-I to F-VII) in Table~\ref{tw-d818a3599e8a} , and time versus cumulative percent release curves in Figure~\ref{f-f3db836d4650} . \unskip~\cite{1927116:28000240}

\textbf{Stability studies of the tablets}

In pharmaceutical formulations, stability refers to the amount of time between the time of manufacture and the time at which either the chemical or biological activity reaches or exceeds a predetermined level of labeled potency, and that the formulation has not undergone any significant physical changes \unskip~\cite{1927116:28000248}. 

Formulation and development should consider a pharmaceutical product's physical and chemical stability and safety. Drug products and substances age, and stability tests show how they change over time. Environmental factors, such as temperature, humidity, and light, can determine storage conditions, retests, and shelf lives. In general, it takes a considerable amount of time to observe how quickly a product degrades at room temperature. We adopt accelerated stability study principles to avoid unwanted delay \unskip~\cite{1927116:28000241}.

In the European Union, Japan and the United States of America, the ICH Guidelines titled "Stability testing of new drug substances and products" (QIA) specify the requirements for stability tests. Storage conditions and study length are specified by ICH. 

Accelerated testing: 402\ensuremath{^\circ}C/75\%  5\% RH for 6 months.

Long{\textendash}term testing: 252\ensuremath{^\circ}C/60\%  5\% RH for 12 months.

The present study was conducted for 12 weeks at 25\ensuremath{^\circ}C/60\% RH and 40\ensuremath{^\circ}C/75\% RH for selected formulations (F-VII).

\textbf{Method}

We evaluated the physical appearance and drug content of certain clear PVC-ALU packed formulations over 12 weeks by storing them at 25\ensuremath{^\circ}C/60\% RH and 40\ensuremath{^\circ}C/75\% RH, respectively. Spectral changes were observed by scanning the formulations again. A dissolution study was also performed in vitro. Table~\ref{tw-9a77689b4c19}  present the results \unskip~\cite{1927116:28000246}\unskip~\cite{1927116:28000237}

\textbf{Drug release kinetics studies}

Graphical analysis was performed on the optimized formulation to determine its release kinetics \unskip~\cite{1927116:28000238}.

\textbf{Zero order plot}

The cumulative release of drugs over time produces a zero-order plot.

\textbf{Higuchi Plot}

An analysis of Higuchi plots is made by plotting a drug's cumulative percentage release against its square root.

\textbf{Koresmeyer Plot }

The graph was obtained by plotting the log cumulative percentage (\%) of drug release vs log time.

\textbf{First-order kinetic release study }

Log remaining cumulative percentage drug release against time was plotted to obtain first-order plots.

\textbf{RESULTS AND DISCUSSION}

An HPLC method was used to analyze the Risperidone calibration curve in a pH 1.2 buffer. Risperidone standard solution with a concentration of 0-10 \ensuremath{\mu }g/ml in Media gave straight-line relationships as indicated. Table~\ref{tw-421d4d71df05}Figure~\ref{f-1a3e5e0fcae3}


\begin{table}[!htbp]
\caption{\boldmath {\textbf{Standard calibration curve of Risperidone in pH 1.2 buffer}} }
\label{tw-421d4d71df05}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LL}
\tbltoprule 
CONCENTRATION (\ensuremath{\mu}g/ml) &
  PEAK AREA (mAU)\\
1 &
  241310\\
2 &
  482580\\
3 &
  723910\\
4 &
  965260\\
5 &
  1206590\\
6 &
  1447860\\
7 &
  1689178\\
8 &
  1930480\\
9 &
  2171800\\
10 &
  2413100\\
\tblbottomrule 
\end{tabulary}\par 
\end{table}

\bgroup
\fixFloatSize{images/189ffb7d-7dea-434d-914b-f3fc23757c1a-uimage.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/189ffb7d-7dea-434d-914b-f3fc23757c1a-uimage.png}{\includegraphics{images/189ffb7d-7dea-434d-914b-f3fc23757c1a-uimage.png}}{\includegraphics{189ffb7d-7dea-434d-914b-f3fc23757c1a-uimage.png}}
\makeatother 
\caption{\boldmath {Standard Calibration Curve of Risperidone in pH1.2 Buffer}}
\label{f-1a3e5e0fcae3}
\end{figure}
\egroup
Using the composition shown in the table, Risperidone orally disintegrating tablets were prepared. F-I contained 2mg Risperidone,121.60mg Mannitol anhydrous, 11.20mg sodium starch glycollate, 0.80mg methylparaben, 0.20mg propylparaben, 1.40mg Aspartame, 0.7mg Sunset yellow, 1.40mg Strawberry flavour, and 0.70mg Magnesium stearate. In formulation-II (F-II), Croscarmellose sodium was substituted for sodium starch glycollate by 11.20 mg.

Formulation III (F-III) used 11.20 mg of Crospovidone instead of Croscarmellose sodium for the remaining ingredients and quantities. In comparison to formulation III, formulation IV (F-IV) had two differences between its ingredients and its quantities. Formulation III contains the same amount of ingredients as Formulation III except that the amount of Mannitol anhydrous has been replaced with Sorbitol granular grade and Crospovidone has been replaced with sodium starchglycollate. In formulation V (F-V), Croscarmellose sodium was substituted for sodium starch glycollate at 11.20 mg. As with formulation IV, there were the same ingredients and amounts. The formulation VI consisted of 11.20 mg of Crospovidone in place of Croscarmellose sodium. There were two changes in formulation VII(F-VII) compared to formulation VI, in addition to the remaining ingredients and quantities. A reduction of 121.60 g was made to 60.80 g of mannitol anhydrous, which was replaced with microcrystalline cellulose 112 grade. Table~\ref{tw-e2ba6a9e0cc6}


\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Composition of Risperidone orally disintegrating tablets}} }
\label{tw-e2ba6a9e0cc6}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LLLLLLLL}
\tbltoprule 
\multicolumn{1}{p{\dimexpr(\mcWidth{1})}}{\multirow{2}{\linewidth}{INGREDIENTS}} &
  \multicolumn{7}{p{\dimexpr(\mcWidth{2}+\mcWidth{3}+\mcWidth{4}+\mcWidth{5}+\mcWidth{6}+\mcWidth{7}+\mcWidth{8})}}{QUANTITY PER TABLET (mg)}\\
 &
  F-I &
  F-II &
  F-III &
  F-IV &
  F-V &
  F-VI &
  F-VII\\
Risperidone &
  2.00 &
  2.00 &
  2.00 &
  2.00 &
  2.00 &
  2.00 &
  2.00\\
Mannitol anhydrous &
  121.6 &
  121.6 &
  121.6 &
  - &
  - &
  - &
  60.80\\
Sorbitol granular grade &
  - &
  - &
  - &
  121.6 &
  121.6 &
  121.6 &
  -\\
Microcrystalline cellulose {\textendash} low moisture grade (MCC-112) &
  - &
  - &
  - &
  - &
  - &
  - &
  60.80\\
Sodium starch glycollate &
  11.20 &
  - &
  - &
  11.20 &
  - &
  - &
  -\\
Croscarmellose sodium &
  - &
  11.20 &
  - &
  - &
  11.20 &
  - &
  -\\
Crospovidone &
  - &
  - &
  11.20 &
  - &
  - &
  11.20 &
  11.20\\
Methylparaben &
  0.80 &
  0.80 &
  0.80 &
  0.80 &
  0.80 &
  0.80 &
  0.80\\
Propylparaben &
  0.20 &
  0.20 &
  0.20 &
  0.20 &
  0.20 &
  0.20 &
  0.20\\
Aspartame &
  1.40 &
  1.40 &
  1.40 &
  1.40 &
  1.40 &
  1.40 &
  1.40\\
Sunset Yellow FCF &
  0.70 &
  0.70 &
  0.70 &
  0.70 &
  0.70 &
  0.70 &
  0.70\\
Strawberry flavour &
  1.40 &
  1.40 &
  1.40 &
  1.40 &
  1.40 &
  1.40 &
  1.40\\
Magnesium stearate &
  0.70 &
  0.70 &
  0.70 &
  0.70 &
  0.70 &
  0.70 &
  0.70\\
The average weight of the tablets &
  140 &
  140 &
  140 &
  140 &
  140 &
  140 &
  140\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Various physicochemical properties of Risperidone powder mixtures before making the tablets by direct compression methods}} }
\label{tw-a33e1535a0d4}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LLLLLL}
\tbltoprule 
FORMULATION &
  ANGLE OF REPOSE (0), \mbox{}\protect\newline \ensuremath{\theta } = tan -1h/r &
  LOOSE BULK DENSITY (LBD) \mbox{}\protect\newline (g/ml) &
  TAPPED BULK DENSITY (TBD) \mbox{}\protect\newline (g/ml) &
  COMPRESSIBILITY INDEX (\%) &
  DRUG CONTENT (\%)\\
F-I  &
  28.56 &
  0.562 &
  0.690 &
  18.55 &
  99.69\\
F-II &
  30.09 &
  0.640 &
  0.745 &
  14.09 &
  99.85\\
F-III &
  25.46 &
  0.305 &
  0.351 &
  13.11 &
  99.57\\
F-IV  &
  24.98 &
  0.317 &
  0.367 &
  13.63 &
  99.32\\
F-V &
  24.23 &
  0.310 &
  0.360 &
  13.89 &
  100.50\\
F-VI &
  25.09 &
  0.318 &
  0.378 &
  15.87 &
  99.87\\
F-VII &
  22.98 &
  0.311 &
  0.368 &
  15.21 &
  99.78\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Various physicochemical properties of Risperidone-loaded orally dispersing tablets prepared by direct compression (F-I to F-VII) methods}} }
\label{tw-1d44d638069e}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LLLLLLLL}
\tbltoprule 
Formulation &
  Average Thickness (mm) &
  Hardness \mbox{}\protect\newline (kg /cm2) \mbox{}\protect\newline (mean \ensuremath{\pm} S.D) &
  Weight Variation \mbox{}\protect\newline (140mg \ensuremath{\pm}10\%) &
  Weight of Tablets before friability  \mbox{}\protect\newline (W1) gm &
  Weight of Tablets after friability (W2) gm &
  Percentage Friability \mbox{}\protect\newline (\%) &
  Drug Content (\%)\\
F-I  &
  3.22\ensuremath{\pm} 0.055 &
  4.20\ensuremath{\pm} 0.32 &
  Pass &
  6.575 &
  6.559 &
  0.24 &
  99.42\\
F-II &
  3.35\ensuremath{\pm} 0.010 &
  3.60\ensuremath{\pm} 0.29 &
  Pass &
  6.597 &
  6.569 &
  0.42 &
  98.55\\
F-III &
  3.40\ensuremath{\pm} 0.017 &
  3.00\ensuremath{\pm} 0.27 &
  Pass &
  6.550 &
  6.517 &
  0.50 &
  98.70\\
F-IV  &
  3.36 \ensuremath{\pm} 0.016 &
  3.50\ensuremath{\pm} 0.49 &
  Pass &
  6.579 &
  6.549 &
  0.46 &
  99.52\\
F-V  &
  3.29 \ensuremath{\pm} 0.020 &
  3.20\ensuremath{\pm} 0.24 &
  Pass &
  6.610 &
  6.589 &
  0.32 &
  99.55\\
F-VI  &
  3.20\ensuremath{\pm} 0.062 &
  4.50\ensuremath{\pm} 0.21 &
  Pass &
  6.532 &
  6.519 &
  0.20 &
  99.87\\
F-VII  &
  3.32\ensuremath{\pm} 0.018 &
  3.90\ensuremath{\pm} 0.22 &
  Pass &
  6.642 &
  6.619 &
  0.35 &
  99.82\\
Marketed sample &
  2.90\ensuremath{\pm} 0.055 &
  4.00\ensuremath{\pm} 0.32 &
  Pass &
  ND &
  ND &
  ND &
  98.69\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{ND {\textendash} not determined: Marketed sample {\textendash} ZisperMD2mg Unichem Laboratories Ltd, Mumbai, India}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Various physicochemical properties of Risperidone-loaded orally dispersing tablets prepared by direct compression (F-I to F-VII) methods}} }
\label{tw-ee40ece25195}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LLLLL}
\tbltoprule 
FORMULATION &
  DISINTEGRATION TEST \mbox{}\protect\newline (NMT 30SEC) &
  DISPERSIBILITY TEST &
  WETTING TIME \mbox{}\protect\newline (SEC) &
  WATER ABSORPTION RATIO\\
F-I  &
  28 &
  Pass &
  102 &
  80.22\\
F-II &
  23 &
  Pass &
  90 &
  85.36\\
F-III &
  18 &
  Pass &
  55 &
  91.24\\
F-IV  &
  24 &
  Pass &
  88 &
  79.25\\
F-V  &
  20 &
  Pass &
  72 &
  87.12\\
F-VI  &
  15 &
  Pass &
  42 &
  86.98\\
F-VII  &
  12 &
  Pass &
  45 &
  92.17\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\bgroup
\fixFloatSize{images/902c0640-de4f-4dbe-9667-61510662e21d-uimage.png}
\begin{figure*}[!htbp]
\centering \makeatletter\IfFileExists{images/902c0640-de4f-4dbe-9667-61510662e21d-uimage.png}{\includegraphics{images/902c0640-de4f-4dbe-9667-61510662e21d-uimage.png}}{\includegraphics{902c0640-de4f-4dbe-9667-61510662e21d-uimage.png}}
\makeatother 
\caption{\boldmath {Comparison of disintegration time of variousformulations}}
\label{f-d3814e3aed47}
\end{figure*}
\egroup

\bgroup
\fixFloatSize{images/166134ad-c702-49d1-91fc-7338931b90b4-uimage.png}
\begin{figure*}[!htbp]
\centering \makeatletter\IfFileExists{images/166134ad-c702-49d1-91fc-7338931b90b4-uimage.png}{\includegraphics{images/166134ad-c702-49d1-91fc-7338931b90b4-uimage.png}}{\includegraphics{166134ad-c702-49d1-91fc-7338931b90b4-uimage.png}}
\makeatother 
\caption{\boldmath {Comparison of wetting time of variousformulations}}
\label{f-2077e5c1e842}
\end{figure*}
\egroup

\bgroup
\fixFloatSize{images/0eec21b7-6236-47ae-9e5a-8a9aa13a3ed8-uimage.png}
\begin{figure*}[!htbp]
\centering \makeatletter\IfFileExists{images/0eec21b7-6236-47ae-9e5a-8a9aa13a3ed8-uimage.png}{\includegraphics{images/0eec21b7-6236-47ae-9e5a-8a9aa13a3ed8-uimage.png}}{\includegraphics{0eec21b7-6236-47ae-9e5a-8a9aa13a3ed8-uimage.png}}
\makeatother 
\caption{\boldmath {Comparison of water absorption ratio ofvarious formulation}}
\label{f-6831327691ca}
\end{figure*}
\egroup

\bgroup
\fixFloatSize{images/940093d1-8b1a-4d94-95be-00e39692283c-upicture-1.png}
\begin{figure*}[!htbp]
\centering \makeatletter\IfFileExists{images/940093d1-8b1a-4d94-95be-00e39692283c-upicture-1.png}{\includegraphics{images/940093d1-8b1a-4d94-95be-00e39692283c-upicture-1.png}}{\includegraphics{940093d1-8b1a-4d94-95be-00e39692283c-upicture-1.png}}
\makeatother 
\caption{\boldmath {Disintegration time for formulation F-VII at various time intervels}}
\label{f-72865e1b3a9c}
\end{figure*}
\egroup
\textbf{In vitro drug Release}


\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Comparison of different formulations of Risperidone in vitro drug release}} }
\label{tw-d818a3599e8a}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.107\linewidth-2\tabcolsep}p{\dimexpr.10270000000000001\linewidth-2\tabcolsep}p{\dimexpr.1203\linewidth-2\tabcolsep}p{\dimexpr.11\linewidth-2\tabcolsep}p{\dimexpr.11\linewidth-2\tabcolsep}p{\dimexpr.11\linewidth-2\tabcolsep}p{\dimexpr.11\linewidth-2\tabcolsep}p{\dimexpr.11\linewidth-2\tabcolsep}p{\dimexpr.12\linewidth-2\tabcolsep}}
\tbltoprule 
\multicolumn{1}{p{\dimexpr(.107\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{TIME \mbox{}\protect\newline (MINS)}} &
  \multicolumn{8}{p{\dimexpr(.893\linewidth-2\tabcolsep)}}{CUMULATIVE PERCENTAGE DRUG RELEASE }\\
 &
  F-I &
  F-II &
  F-III &
  F-IV &
  F-V &
  F-VI &
  F-VII &
  Marketed std\\
2  &
  32.16  &
  45.65  &
  52.21  &
  39.15  &
  63.12  &
  72.16  &
  73.30  &
  69.10 \\
4  &
  53.60  &
  60.22  &
  70.53  &
  55.00  &
  75.05  &
  87.64 &
  86.15  &
  80.15 \\
6  &
  68.50  &
  73.86  &
  77.65  &
  62.18  &
  85.37  &
  95.93 &
  96.35  &
  95.57 \\
8  &
  82.00  &
  83.06  &
  90.12  &
  89.16  &
  91.68  &
  97.32  &
  98.82  &
  99.59 \\
10  &
  96.50  &
  99.65  &
  99.82  &
  98.56  &
  98.25  &
  99.72 &
  99.82  &
  99.92 \\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\bgroup
\fixFloatSize{images/98ec2bc3-12f9-49e7-8cc5-b42386e4d97e-uimage.png}
\begin{figure*}[!htbp]
\centering \makeatletter\IfFileExists{images/98ec2bc3-12f9-49e7-8cc5-b42386e4d97e-uimage.png}{\includegraphics{images/98ec2bc3-12f9-49e7-8cc5-b42386e4d97e-uimage.png}}{\includegraphics{98ec2bc3-12f9-49e7-8cc5-b42386e4d97e-uimage.png}}
\makeatother 
\caption{\boldmath {\textbf{Comparison of different formulations of Risperidone in vitro drug release}}}
\label{f-f3db836d4650}
\end{figure*}
\egroup

\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Comparative In vitro evaluation of }\textbf{Risperidone}\textbf{ Marketed sample and optimized Test Formulation}\textbf{ (F-VII} \textbf{)}} }
\label{tw-81d88bd62e8c}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LLLL}
\tbltoprule 
S.NO. &
  TIME  \mbox{}\protect\newline (MINS)  &
  CUMULATIVE PERCENTAGE DRUG RELEASE OF F-VII  &
  CUMULATIVE PERCENTAGE DRUG RELEASE OF MARKETED SAMPLE \mbox{}\protect\newline (ZISPER MD2MG) \\
1 &
  2  &
  73.30  &
  69.10 \\
2 &
  4  &
  86.15  &
  80.15 \\
3 &
  6  &
  96.35  &
  95.57 \\
4 &
  8  &
  98.82  &
  99.59 \\
5 &
  10  &
  99.82  &
  99.92 \\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\bgroup
\fixFloatSize{images/eef909e8-eca5-4fc9-9694-57e6399490fd-uimage.png}
\begin{figure*}[!htbp]
\centering \makeatletter\IfFileExists{images/eef909e8-eca5-4fc9-9694-57e6399490fd-uimage.png}{\includegraphics{images/eef909e8-eca5-4fc9-9694-57e6399490fd-uimage.png}}{\includegraphics{eef909e8-eca5-4fc9-9694-57e6399490fd-uimage.png}}
\makeatother 
\caption{\boldmath {\textbf{Comparative In vitro evaluation of }\textbf{Risperidone}\textbf{ Marketed sample and optimized Test Formulation}\textbf{ (F-VII} \textbf{)}}}
\label{f-7ef74dfa7baa}
\end{figure*}
\egroup
Storage conditions: 25\ensuremath{^\circ}C \ensuremath{\pm}2 at 60\% \ensuremath{\pm}5\%RH

Description: Uncoated, Pale orange, Oval shaped tablets


\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Stability Data of }\textbf{Risperidone F-VII}\textbf{\space }\textbf{Orally Disintegrating }\textbf{Tablets} \textbf{\space }} }
\label{tw-9a77689b4c19}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LLLLLL}
\tbltoprule 
S.NO &
   TESTS &
   INITIAL MONTH &
  1ST MONTH &
  2ND MONTH &
  3RD MONTH\\
1. &
  Description &
  Complies &
  Complies &
  Complies &
  Complies\\
2. &
  Average weight 126-154mg &
  141.50 mg &
  140.37 mg &
  140.89 mg &
  140.11 mg\\
3. &
  Average Thickness \mbox{}\protect\newline 3.20mm -3.40mm &
  3.26 mm &
  3.22 mm &
  3.28 mm &
  3.22 mm\\
4. &
  Average Hardness &
  4.0 kg/cm2 &
  4.0 kg/cm2 &
  4.0kg/cm2 &
  4.0 kg/cm2\\
5. &
  Friability \mbox{}\protect\newline NMT 1.0 \% &
   0.14\% &
  0.17\% &
  0.25\% &
  0.3.2\%\\
6. &
  Dissolution Profile \mbox{}\protect\newline (Cumulative \% drug release) &
  2mins-73.30 \mbox{}\protect\newline 4mins-86.15 \mbox{}\protect\newline 6mins-96.35 \mbox{}\protect\newline 8mins-98.82 \mbox{}\protect\newline 10mins-99.82 &
  2mins-74.38 \mbox{}\protect\newline 4mins-87.90 \mbox{}\protect\newline 6mins-96.12 \mbox{}\protect\newline 8mins-99.12 \mbox{}\protect\newline 10mins-99.92 &
  2mins-76.10 \mbox{}\protect\newline 4mins-85.99 \mbox{}\protect\newline 6mins-97.98 \mbox{}\protect\newline 8mins-98.95 \mbox{}\protect\newline 10mins-9915 &
  2mins-72.78 \mbox{}\protect\newline 4mins-83.13 \mbox{}\protect\newline 6mins-91.39 \mbox{}\protect\newline 8mins-97.85 \mbox{}\protect\newline 10mins-98.96\\
7. &
  Assay of Risperidone &
  99.28\% &
  99.52\% &
  99.75\% &
  99.72\%\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{DISCUSSION}

Risperidone is an atypical antipsychotic agent used in the treatment of schizophrenia, bipolar disorder, and other mental illnesses. Orally disintegrating tablets (ODTs) have gained popularity in recent years due to their ease of administration and faster onset of action compared to traditional tablets. In this study, we aimed to formulate and evaluate Risperidone ODTs. Formulation of Risperidone ODTs was done using a direct compression method. The tablets were prepared using a blend of Risperidone, crospovidone, microcrystalline cellulose, and mannitol as the active ingredient, super disintegrant, filler, and sweetener, respectively. 

The formulation was optimized by changing the concentration of the super disintegrant, which was found to be the critical parameter affecting the disintegration time of the tablets. The ODTs were evaluated for various parameters, including weight variation, hardness, friability, drug content, and disintegration time. The results showed that the tablets were within the acceptable limits for all parameters. The disintegration time of the optimized formulation was found to be 18 seconds, which is within the range specified by the United States Pharmacopeia (USP) for ODTs. The high concentration of crospovidone in the formulation was responsible for the rapid disintegration of the tablets. The in vitro dissolution study was performed using the USP type II dissolution apparatus. The results showed that more than 85\% of the drug was released within 10 minutes, indicating the rapid onset of action of the ODTs. The dissolution profile of the ODTs was compared with that of the marketed conventional tablet, and the results showed that the ODTs had a faster dissolution rate, confirming the advantage of ODTs over conventional tablets. The stability study of the ODTs was performed for three months under accelerated conditions (25\ensuremath{^\circ}C and 60\% relative humidity). The results showed that there were no significant changes in the physical appearance, drug content, and dissolution profile of the tablets. Thus, the ODTs were found to be stable under accelerated conditions.

\textbf{CONCLUSION}

The present study demonstrated that Risperidone ODTs can be successfully formulated using a direct compression method. The formulation and evaluation of risperidone ODTs were successfully carried out, and the results showed that the formulated ODTs had excellent characteristics such as rapid disintegration time, acceptable drug content, and a similar dissolution profile to the marketed risperidone tablets. The use of super disintegrants such as crospovidone and croscarmellose sodium in the formulation played a significant role in achieving rapid disintegration. Moreover, the use of mannitol, aspartame, and magnesium stearate as a lubricant helped in maintaining the structural integrity of the ODTs. The stability study showed that the ODTs were stable under accelerated conditions for three months. Therefore, Risperidone ODTs could be a potential alternative to conventional tablets for the treatment of mental illnesses, especially for patients who have difficulty swallowing conventional tablets.

\textbf{Funding Support}

The authors declare that they have no funding support for this study.

\textbf{Conflict of Interest}

The authors declare that there is no conflict of interest.
    

\bibliographystyle{unsrt}

\bibliography{\jobname}
\end{document}
